Table 6.
Comparison of patients parameters according to complications and mortality in the peri-COVID group.
| Laboratory Parameters |
With Complications |
Without Complications |
p | Deceased n = 36 |
Alive n = 213 |
p |
|---|---|---|---|---|---|---|
| Gender (M/F) |
21/19 (52.5%/47.5%) |
106/103 (52.5%/47.5%) |
0.388 † | 21/15 58.3%/41.7% |
70/90 43.8%/56.3% |
0.113 † |
| Age | 61.73 ± 2.74 | 64.57 ± 1.28 | 0.561 | 63.08 ± 2.73 | 64.19 ± 1.29 | 0.714 |
| Hours_onset | 46.75 ± 4.96 | 35.81 ± 1.96 | 0.091 | 44.08 ± 4.31 | 36.68 ± 2.08 | 0.128 |
| Area (U/R) |
12/28 30%/70% |
85/71 54.5%/45.5% |
0.006 *† | 15/21 41.7%/58.3% |
82/78 51.2%/48.8% |
0.299 † |
| Proteins | 5.89 ± 0.14 | 6.36 ± 0.07 | <0.001 * | 5.81 ± 0.15 | 6.37 ± 0.06 | 0.001 * |
| Amylase | 598.03 ± 100.13 | 597.99 ± 58.47 | 0.513 | 758.03 ± 105.27 | 561.53 ± 57.18 | 0.132 |
| AST | 142.83 ± 237.83 | 57.90 ± 58.53 | 0.910 | 252.17 ± 343.29 | 97.56 ± 106.92 | 0.023 * |
| ALT | 138.21 ± 197.66 | 163.05 ± 188.02 | <0.001 * | 113.73 ± 149.93 | 151.50 ± 185.64 | 0.022 * |
| BT | 2.86 ± 4.76 | 2.37 ± 3.71 | 0.494 | 5.61 ± 7.13 | 1.75 ± 2.20 | 0.003 * |
| Urea | 76.95 ± 8.85 | 50.94 ± 3.73 | 0.600 | 95.17 ± 13.47 | 47.45 ± 2.66 | 0.001 * |
| Creatinine | 2.67 ± 0.41 | 1.2 ± 0.10 | 0.664 | 3.35 ± 0.48 | 1.08 ± 0.07 | <0.001 * |
| Glucose | 145.93 ± 16.02 | 126.63 ± 5.34 | 0.010 * | 185.39 ± 18.24 | 47.45 ± 2.66 | 0.001 * |
| INR | 1.26 ± 0.04 | 1.21 ± 0.03 | 0.924 | 1.39 ± 0.06 | 1.18 ± 0.02 | 0.001 * |
| COVID-19 | 9/32.1% | 31/18.5% | 0.097† | 12/42.9% | 24/14.3% | <0.001 *† |
| Hb (g/dl) | 12.15 ± 0.45 | 13.10 ± 0.16 | 0.044 | 11.77 ± 0.55 | 13.16 ± 0.15 | 0.019 * |
| Ht (%) | 36 ± 1.23 | 38.5 ± 0.61 | 0.364 | 34.17 ± 1.40 | 38.85 ± 0.57 | 0.003 * |
| WBC (×103/μL) | 13.18 ± 6.75 | 10.01 ± 8.89 | 0.629 | 15.82 ± 9.63 | 13.15 ± 5.78 | 0.118 |
| NEU (×103/μL) | 11.09 ± 6.01 | 11.19 ± 6.57 | 0.927 | 13.86 ± 8.94 | 10.57 ± 5.60 | 0.040 * |
| LYM (×103/μL) | 1.18 ± 0.84 | 1.62 ± 1.34 | 0.050 | 0.99 ± 0.50 | 1.65 ± 1.35 | <0.001 * |
| MON (×103/μL) | 0.84 ± 0.37 | 1 ± 1.34 | 0.458 | 0.85 ± 0.44 | 0.99 ± 1.32 | 0.519 |
| PLT (×103/μL) | 191.69 ± 124.72 | 218.42 ± 110.58 | 0.186 | 168.59 ± 125.62 | 22.95 ± 108.90 | 0.009 * |
| MCV (fL) | 99.63 ± 5.12 | 92.02 ± 7.31 | <0.001 * | 103.46 ± 4.70 | 91.35 ± 6.17 | <0.001 * |
| RDW | 13.83 ± 1.79 | 13.43 ± 1.39 | 0.191 | 14.57 ± 1.9 | 13.27 ± 1.26 | <0.001 * |
| NLR | 11.49 ± 7.15 | 9.92 ± 8.95 | 0.305 | 14.86 ± 7.72 | 9.20 ± 8.49 | <0.001 * |
| PLR | 171.01 ± 74.68 | 171.90 ± 111.94 | 0.962 | 175.99 ± 105.89 | 170.76 ± 105.41 | 0.788 |
| MLR | 0.94 ± 0.66 | 0.74 ± 0.79 | 0.138 | 1.07 ± 0.72 | 0.71 ± 0.77 | 0.011 * |
| dNLR | 8.20 ± 12.50 | 5.53 ± 3.92 | 0.191 | 7.18 ± 4.42 | 5.83 ± 7.08 | 0.275 |
| AISI | 1738.37 ± 1569.47 | 2161.59 ± 3078.57 | 0.226 | 2604.11 ± 2810.62 | 1956.22 ± 2797.18 | 0.211 |
| SIRI | 8.84 ± 4.75 | 9.39 ± 12.07 | 0.654 | 12.98 ± 9.39 | 8.45 ± 11.16 | 0.025 * |
| SII | 1865.62 ± 1255.04 | 2125.78 ± 2375.22 | 0.505 | 2477.51 ± 2015.04 | 1981.60 ± 2227.2 | 0.221 |
| MCVL | 128.53 ± 99.54 | 80.93 ± 52.10 | 0.005 * | 146.64 ± 104.99 | 78.05 ± 47.27 | <0.001 * |
| IIC | 17.20 ± 10.28 | 12.20 ± 10.73 | 0.009 * | 12.12 ± 9.24 | 10.99 ± 9.86 | <0.001 * |
* p < 0.05—statistically significant. † Chi-square test. AST—aspartate aminotransferase, ALT—alanine aminotransferase, BT—total bilirubin, WBC—leukocytes, NEU—neutrophils, LYM—lymphocytes, MON—monocytes, PLT—platelets, MCV—mean corpuscular volume, RDW—erythrocyte distribution width, NLR—neutrophil–lymphocyte ratio, PLR—platelet–lymphocyte ratio, MLR—monocyte–lymphocyte ratio, dNLR—derived neutrophil–lymphocyte ratio, AISI—aggregate index of systemic inflammation, SIRI—systemic inflammatory response index, SII—systemic immune-inflammation index, MCVL—average corpuscular volume–lymphocytes ratio, IIC—cumulative inflammatory index.